: Developmental Funds have continued to play a key role in the global reorganization of the Cancer Center that was initiated during the last CCSG budget period. Supported by a thorough, transparent and inclusive strategic planning process, the Cancer Center has undergone major changes in its administrative infrastructure, refinement of scientific and educational objectives, expansion of programmatic themes and global realignment of Shared Resources. A pivotal aspect of this reorganization was a focused and thematic faculty recruitment effort that led to the hiring of nine new Cancer Center members at all academic ranks and appointed across the three scientific Programs during the last budget period. Judiciously deployed as part of a flexible, inclusive and goal-oriented decision-making process, CCSG Developmental Funds have been instrumental to enable the long-range directives ofthe 2012 Cancer Center Strategic Plan, contributing to new faculty recruitment, facilitating inter-programmatic and collaborative pilot projects, supporting the launch of a new developmental Translational Research Management core, and expanding the collection of clinically annotated primary tumor samples for molecular validation studies, prognostic biomarker assessment and identification of new cancer targets. In this context, CCSG Developmental Funds have tangibly contributed to the sharp upward trajectory of the Cancer Center of the last budget period, reflected in significantly increased cancer focus, growth in NCI and cancer-related funding, expansion of inter- and intraprogrammatic collaborative publications, and launch of a portfolio of scientific initiatives along the continuum of basic, translational and patient-oriented cancer research. Building on these validated principles, CCSG Developmental Funds will continue to support the upward trajectory of the Cancer Center over the next budget period, supporting new faculty recruitment and expanding the Center-wide tools that have been put in place to enable translational and patient-oriented cancer research across all three scientific Programs.

Public Health Relevance

CCSG Developmental Funds have provided a critical asset to enable the transformative changes introduced in the Cancer Center during the last CCSG budget period, especially in the areas of new faculty recruitment and translational cancer research. A detailed plan has been formulated to build on these accomplishments and continue on the trajectory of growth of the cancer research agenda ahead of the upcoming faculty and facility expansion

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA010815-45
Application #
8690275
Study Section
Subcommittee G - Education (NCI)
Project Start
2014-03-01
Project End
2019-02-28
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
45
Fiscal Year
2014
Total Cost
$446,848
Indirect Cost
$203,387
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Tomescu, Costin; Tebas, Pablo; Montaner, Luis J (2017) IFN-? augments NK-mediated antibody-dependent cellular cytotoxicity (ADCC) of HIV-1 infected autologous CD4+ T cells regardless of MHC-I downregulation. AIDS :
Vitiello, Marianna; Tuccoli, Andrea; D'Aurizio, Romina et al. (2017) Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget 8:25395-25417
Veglia, Filippo; Gabrilovich, Dmitry I (2017) Dendritic cells in cancer: the role revisited. Curr Opin Immunol 45:43-51
Hoffman, Hunter; Rice, Cory; Skordalakes, Emmanuel (2017) Structural Analysis Reveals the Deleterious Effects of Telomerase Mutations in Bone Marrow Failure Syndromes. J Biol Chem 292:4593-4601
Lu, Fang; Wiedmer, Andreas; Martin, Kayla A et al. (2017) Coordinate Regulation of TET2 and EBNA2 Control DNA Methylation State of Latent Epstein-Barr Virus. J Virol :
Karpel-Massler, Georg; Ishida, Chiaki Tsuge; Bianchetti, Elena et al. (2017) Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses. Cancer Res 77:3513-3526
Lynch, Shannon M; Mitra, Nandita; Ravichandran, Krithika et al. (2017) Telomere Length and Neighborhood Circumstances: Evaluating Biological Response to Unfavorable Exposures. Cancer Epidemiol Biomarkers Prev 26:553-560
Perales-Puchalt, Alfredo; Svoronos, Nikolaos; Rutkowski, Melanie R et al. (2017) Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target. Clin Cancer Res 23:441-453
Pestell, Timothy G; Jiao, Xuanmao; Kumar, Mukesh et al. (2017) Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth. Oncotarget 8:81754-81775
Noguchi, Shuhei; Arakawa, Takahiro; Fukuda, Shiro et al. (2017) FANTOM5 CAGE profiles of human and mouse samples. Sci Data 4:170112

Showing the most recent 10 out of 685 publications